Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Johnson & Johnson

Suspected North Korean hackers have recently tried to break into at least nine health organizations, including pharmaceutical giant Johnson & Johnson and vaccine developer Novavax Inc, revealing a broader effort to target key players in the race to develop treatments for COVID-19.

North Korea-linked hackers targeted J&J, Novavax in hunt for COVID research

AstraZeneca

BioNTech SE

CureVac B.V

Moderna

Pfizer

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

COVID Vaccine Stocks Update: Where Things Stand Now

AbbVie

Inovio Pharmaceuticals

Regeneron Pharmaceuticals

Now that companies such as Pfizer, Moderna and AstraZeneca have emerged with viable vaccines against Covid-19, the hype around many pharmaceutical stocks is fading. Here are four stocks investors should be weary of in the weeks ahead.

4 Pharmaceutical Stocks That Aren't Worth Their Outsized 2020 Gains

Novavax (NVAX) to begin a phase III study on NVX-CoV2373, its COVID-19 vaccine candidate in the United States and Mexico in the coming weeks. Shares up.

Novavax (NVAX) Rises Despite U.S. Coronavirus Vaccine Study Delay

Novavax's Late-Stage COVID Vaccine Trial in U.S. Delayed Again: Should Investors Worry?

Novavax said Monday it's planning to begin the U.S.-based study of its coronavirus vaccine "in the coming weeks," and NVAX stock popped. The study was initially set to begin in November.

Novavax Reverses Earlier Losses As It Plans U.S. Covid Vaccine Test

The stock price of Novavax, Inc. (NASDAQ: NVAX) closed up 10.99% today as it went from $125.69 to $139.65 per share today. This is why.

NVAX Stock Price Increases 10.99%: Why It Happened

A new week brings updates from both NVAX and MRNA. Detailed numbers from MRNA's COVE study confirm the value of MRNA's vaccine, but is the company's pipeline validated?

Novavax Makes Progress, Is The Name A Discount Moderna?

Citi Trends

Louisiana-Pacific

Nautilus

Ultra Clean

Unisys

VirnetX

Vaxart

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

Top Small Cap Stocks for December 2020

Novavax retraced a premarket slump and jumped as much as 9.7% on Monday after offering updates to various COVID-19 vaccine studies. The biotech company announced Monday that it completed enrollment of its 15,000-participant trial in the UK. Interim data from the phase 3 study is expected as soon as the first quarter of 2021. Timing is still contingent on the coronavirus infection rate in the UK, according to a press release. If successful, the data can support applications for regulatory approval in the UK and European Union.

Novavax climbs 11% after announcing data from UK vaccine trial are expected in early 2021

NVAX stock is set to move higher once its Covid-19 vaccine is ready. If its clinical trials succeed, NVAX stock is worth $165 per share, or 61% higher than today.

Novavax Is Worth $165 Once Its Covid-19 Vaccine Is Ready

Beyond Meat

Walmart

Costco

Tesla

Zoom Video

Buy low, sell high. Here are some stocks that are very high, on which you can take profits now.

7 Stocks to Sell for Christmas Giving

GAITHERSBURG, Md., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax' proprietary Matrix‑M™.

Novavax Announces COVID-19 Vaccine Clinical Development Progress

The small biotech's promising coronavirus vaccine candidate is only half of the reason.

Why Novavax Could Be a Bigger COVID Vaccine Winner Than Pfizer and Moderna

Here's what makes these coronavirus-focused biotechs stand out.

3 COVID Vaccine Stocks That Could Be Millionaire-Makers

Sorrento Therapeutics Inc

The Nasdaq Composite pushed further into all-time high territory Friday morning.

These 3 Coronavirus Vaccine Stocks Are Lifting the Nasdaq to New Records

AstraZeneca's slip is sending these two biotechs higher today.

Why Moderna and Novavax Shares Are Racing Higher Today

Telesis Bio Inc

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.

4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts

Novavax finally found a bottom, and prices are headed higher. Here's a smart trade to game the next move in NVAX stock.

Novavax Stock Is Ready to Shoot Higher Again

Although Pfizer and Moderna have stolen the headlines, there are still ample opportunities for upside with NVAX stock. The post Overlook Novavax at the Risk of Incurring an Opportunity Cost appeared first on InvestorPlace.

Overlook Novavax at the Risk of Incurring an Opportunity Cost

Abbott Labs

Gilead Sciences

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race for a Vaccine appeared first on InvestorPlace.

7 Biotech Stocks That Are Locked in the Race for a Vaccine

These dark horses are getting their second wind.

3 Long-Shot Coronavirus Vaccine Stocks to Watch in December

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates expressed optimism on the efficacy of COVID-19 vaccines made by various drugmakers in an interview with CNN on Sunday. What Happened: The billionaire told CNN's Fareed Zakaria that while vaccines from Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) have already shown effectiveness against COVID-19 in early data, he expects similar results from AstraZeneca Plc (NYSE: AZN), Johnson & Johnson (NYSE: JNJ) and Novavax, Inc (NASDAQ: NVAX) vaccines.

Bill Gates Says AstraZeneca, Johnson & Johnson, Novavax COVID-19 Vaccines All Likely To Prove 'Very Efficacious And Safe' By February

Here are ideas for both conservative and aggressive investors.

Top COVID Vaccine Stocks to Buy Now

Pfizer and Moderna have reported vaccine efficacy of over 90%. What should Novavax investors expect?

News for Novavax Stock (NVAX)